Jeff Gordon Childrens Foundation

“A copy of the Form 990 is provided to the Chief Financial Officer and it is reviewed and approved by the Board prior to filing.”

“Each director, principal officer and member of a committee with governing board delegated powers shall annually sign a statement which affirms such person:a. Has received a copy of the conflicts of interest policy,b. Has read and understands the policy,c. Has agreed to comply with the policy, andd. Understands the Foundation is charitable and in order to maintain its federal tax exemption it must engage primarily in activities which accomplish one or more of its tax exempt purposes.”

“The President and the Board of Directors Chairman review salaries and bonuses.”

“The Annual Report is available on the Organization's website.”

“Client Note 1 - Related Party Payroll Administrator All of Foundation's staff is employed directly by Jeff Gordon, Inc. as disclosed in Schedule L. This relationship exists in order to miminize overall payroll and related benefit costs incurred by the Foundation.”

“OTHER PROGRAM SERVICES 4: OTHER PROGRAM SERVICES 5: Memorial Sloan Kettering Cancer CenterNeuroblastoma frequently is only diagnosed after the disease has spread from the primary tumor site to multiple metastatic sites. This typically requires systemic chemotherapy affecting all parts of the body leading to unintended side effects. In the past recurrent metastatic neuroblastoma was treated with high doses of toxic chemotherapy requiring bone marrow transplant rescue due to the destruction of the patients blood producing bone marrow. These unintended off-target toxicities are well known even with todays precision medicines. Some of these toxicities could be life-long. The ultimate goal of drug development is to find a way to deliver medicine selectively to tumor cells, and not to normal bone marrow, the immune system, kidney, or other vital organs. The team has recently developed a system whereby we can control drug delivery with such precision that toxicity only occurs where the drug is picked up by tumor cells. This Self-assembly/Disassembly (SADA) therapeutic is composed of a multimeric bispecific antibody (BsAb) fragments that can bind to surface antigens on tumor cells and radioactive payload. These BsAbs fragment were engineered to spontaneously assemble into a multimeric SADA complex. Due to its multimeric nature, the SADA complex has enhanced cooperative binding (avidity) to the tumor target, increasing specificity to the target cells or tissues and extending initial serum half-life, while reducing non-specific binding to bystander targets and decreasing toxicity. At non-tumor sites, the SADA complex can spontaneously disassemble into smaller fragments which allow for rapid renal clearance from the body.”